What did @realdrbae actually say?
The creator claimed that compounded GLP-1 medications are essentially identical to brand-name drugs like Ozempic, with the only real difference being the delivery device. They also argued that when a drug comes off the FDA shortage list, compounding pharmacies can legally continue making it by changing the formulation, and that those modified versions are "even better than the name brand." That last part is where things get genuinely problematic.
The video touches on real concepts, including FDA-registered API suppliers and the role of additive ingredients like B12. But the framing collapses important regulatory and pharmacological distinctions in ways that could mislead patients making real treatment decisions. When a creator with 258K views on a video tells people a compounded product is superior to an FDA-approved drug, that deserves scrutiny, not a pass.
Does the science back this up?
Partially, but not in the ways that matter most. The active ingredient in compounded semaglutide, when sourced from an FDA-registered manufacturer, is chemically the same molecule. That part is defensible. The rest gets complicated fast.
The FDA has been explicit that compounded drugs are not FDA-approved and have not undergone the agency's review for safety, efficacy, or manufacturing quality, even when the active ingredient is the same. A 2023 FDA guidance document on 503A and 503B compounding pharmacies reinforced this point, noting that compounded versions are not considered equivalent to approved drugs. The claim that additives like B12 or glycine make compounded versions "even better" is not supported by peer-reviewed clinical evidence. Glycine's role in lean mass preservation during GLP-1 therapy is speculative at best. There are no published randomized controlled trials comparing outcomes between additive-enhanced compounded semaglutide and brand-name semaglutide in humans.
What did they get wrong (or right)?
Credit where it is due: the creator accurately describes that compounding pharmacies source active pharmaceutical ingredients from FDA-registered suppliers, and that compounded versions typically come in vials rather than prefilled autoinjectors. Those are true statements.
Where the video goes wrong is significant. First, saying the only difference is "a fancy injector pen" ignores the entire regulatory apparatus that surrounds FDA approval, including standardized dosing, sterility testing, stability data, and post-market surveillance. Second, the claim that compounding pharmacies can legally continue producing a drug after it comes off the shortage list by simply "changing up the formulation" misrepresents the law. The FDA removed semaglutide from its shortage list in 2024, and subsequently issued guidance stating that 503A and 503B pharmacies generally may not compound copies of commercially available drugs. Changing the formulation does not automatically create a legal carve-out. Third, and most directly: claiming the compounded version is "even better" is an extraordinary claim with no clinical trial evidence behind it. That is not an opinion. That is a gap in the evidence base.
What should you actually know?
If you are considering compounded semaglutide, here is what the current evidence and regulatory landscape actually support. Compounded semaglutide was legally permitted during the FDA shortage period, which ended in 2024. With the shortage resolved, the legal status of compounded semaglutide has shifted, and patients and prescribers should verify current FDA guidance before proceeding.
Compounded drugs are not FDA-approved. That does not automatically make them dangerous, but it does mean they have not gone through the same standardized quality and efficacy review as Ozempic or Wegovy. The active molecule may be identical, but formulation, concentration accuracy, and sterility cannot be assumed equivalent without independent verification. Additives like B12 are not approved for inclusion by the FDA and have not been studied in combination with semaglutide in clinical trials. A prescriber recommending compounded semaglutide should be able to explain the sourcing, the pharmacy's 503A or 503B status, and the specific formulation, not just say it is "the same thing."
The bottom line
This video gets some basics right and then takes several steps too far. The delivery device difference is real. The API sourcing point is real. But equating compounded and brand-name semaglutide as clinically identical, and then arguing compounded versions are superior because of unevidenced additives, crosses from education into advocacy for a specific product category. Patients deserve more precision than that, especially when the regulatory ground is actively shifting.